In the extended analysis of RAS wild-type tumours ( n = @ ) , objective response was significantly improved by addition of cetuximab to FOLFOX@ ( @ % versus @ % ; odds ratio @ -LSB- @ % confidence interval @-@ @ -RSB- ; P = @ ) ; although limited by population size , there also appeared to be trends favouring the cetuximab arm in terms of PFS and overall survival in the RAS wild-type group compared with the RAS evaluable group .